Acetaminophen is the most popular pain reliever in the U.S., accounting for an estimated 27 billion annual doses as of 2009. With 100,000-plus hospital visits a year by users, it's also the most likely to be taken inappropriately. In fact, improper use, coupled with the drug's narrow safety margin, means "a large fraction of users [are] close to a toxic dose in the ordinary course of use," according to the Food and Drug Administration.
But for the sake of discussion, let's ignore the safety issues for a moment. Is acetaminophen an effective pain reliever in the first place? Not for low back pain and pain attributable to knee / hip osteoarthritis, conclude the authors of a recent meta-analysis. The just-published review of 13 randomized trials has yielded "high-quality evidence" that paracetamol (acetaminophen) does not reduce pain intensity or disability, and does not improve quality of life, in the short term for people experiencing LBP; and provides only "minimal, short-term benefit" for people suffering from hip or knee pain caused by OA, stating that "the small effects ... are not likely to be meaningful for clinicians or patients."
Back to the safety issues surrounding acetaminophen, which the meta-analysis did little to dilute. According to the review researchers, "high-quality" evidence suggests paracetamol use results in a fourfold risk of an abnormal liver function test. Not surprising, since acetaminophen misuse (overdose) is now the most common cause of acute liver failure (exceeding all other medications combined) and the second most common cause of liver failure requiring transplantation.
In fact, the FDA has mandated that all acetaminophen-containing prescription products feature a "black box" warning (the administration's strongest safety statement) noting an overdose can cause liver failure and even death; and have been urged to place similar language on OTC acetaminophen products.
Assessing the Evidence
The review researchers performed a systematic electronic search in Medline, Embase, AMED, CINAHL, Web of Science, LILACS, International Pharmaceutical Abstracts, and Cochrane Central Register of Controlled Trials up to December 2014, selecting only randomized, controlled trials comparing paracetamol to placebo for nonspecific spinal pain (neck or LBP), or osteoarthritis of the hip or knee. Trials eligible for inclusion also had to report on one or more of these primary outcome measures: pain intensity, disability status and quality of life. (Secondary outcome measures included adverse effects, patient compliance and use of rescue meds.)
Overall, 13 studies met inclusion criteria and served as the basis for the analysis. Three trials consisting of 1,825 patients evaluated paracetamol for LBP; 10 trials evaluated efficacy for patients (3,541) with hip or knee OA.
In the reviewed studies, paracetamol was primarily administered orally (as tablets / capsules); one study evaluated intravenous paracetamol use by participants with chronic LBP. Total oral dose and dose regimens varied (3,900-4,000 mg/day in 10 trials; 3,000 mg/day in three trials).
After analyzing the eligible study pool, the reviewers even performed "a post-hoc analysis to assess the effect of a new trial in our meta-analysis," which only served to confirm their original findings: "The results of a new trial added to current evidence would not change the conclusion that paracetamol does not deliver a clinically important benefit (at least 9 points out of a 0-100 range) for spinal pain and osteoarthritis."
Clinical Applications
What percentage of your existing patient base uses acetaminophen-containing OTC and/or prescription medications for their LBP and OA pain, even as they pursue relief through chiropractic care? If you don't know, it's time to find out. Now imagine how many current non-patients take these drugs for their spinal / OA pain instead of visiting your office. As this meta-analysis suggests, acetaminophen is ineffective for these types of pain. What an opportunity for chiropractic to become the primary conservative pain-relief option. The research-backed result for your patients (and soon-to-be patients): less medication (mis)use and more pain relief.
Resources
Many relevant diagnostic signs are not performed deliberately by the examiner or by the patient at the examiner’s direction. They are observed as the patient reacts to their condition. Fortin’s finger sign, Minor’s sign, and Vanzetti’s sign are three examples of this principle.
Spearheaded by burgeoning scientific and clinical research literature, psychedelics have reached a level of media coverage and popular interest that has not been seen for over half a century. By “psychedelics,” we are referring to the unique class of substances that includes psilocybin (the active compound found in so-called “magic mushrooms”), LSD, dimethyltryptamine (DMT), ayahuasca, 5-MeO-DMT, and mescaline – each of which occurs in the natural world (except for LSD, which is a semi-synthetic compound).
While working at the Lovelace Medical Center in Albuquerque, N.M., one of the primary care physicians stated that imaging every patient prior to receiving chiropractic was not medically necessary. It was at that point I reconsidered the need for the imaging of every patient to avoid malpractice.
